EXACT Sciences (EXAS) Issues Quarterly Earnings Results

EXACT Sciences (NASDAQ:EXAS) released its quarterly earnings results on Thursday. The medical research company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.11, Briefing.com reports. The business had revenue of $87.41 million during the quarter, compared to analysts’ expectations of $87.42 million. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm’s revenue for the quarter was up 148.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.34) EPS.

Shares of EXACT Sciences (NASDAQ:EXAS) traded down $1.65 during trading on Thursday, hitting $44.99. The stock had a trading volume of 3,012,238 shares, compared to its average volume of 3,200,000. EXACT Sciences has a 12-month low of $19.91 and a 12-month high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01. The stock has a market cap of $5,390.00, a PE ratio of -39.12 and a beta of 0.58.

Several research firms have weighed in on EXAS. Leerink Swann restated an “outperform” rating and set a $67.00 price target (up previously from $63.00) on shares of EXACT Sciences in a report on Monday, November 13th. Robert W. Baird cut EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price target for the company. in a report on Monday, November 13th. Bank of America lifted their target price on EXACT Sciences from $58.00 to $67.00 and gave the stock a “buy” rating in a report on Wednesday, November 29th. Zacks Investment Research cut EXACT Sciences from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, BTIG Research cut EXACT Sciences from a “buy” rating to a “neutral” rating in a report on Wednesday, November 1st. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $52.84.

In related news, SVP D Scott Coward sold 1,665 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total transaction of $87,479.10. Following the completion of the transaction, the senior vice president now owns 37,558 shares in the company, valued at approximately $1,973,297.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin T. Conroy sold 101,488 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $45.72, for a total value of $4,640,031.36. Following the transaction, the insider now owns 931,540 shares of the company’s stock, valued at approximately $42,590,008.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 630,125 shares of company stock valued at $32,597,655. 4.00% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “EXACT Sciences (EXAS) Issues Quarterly Earnings Results” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://stocknewstimes.com/2018/02/23/exact-sciences-exas-issues-quarterly-earnings-results.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Earnings History for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply